Development Asset Leader, Liver Franchise

Prime Medicine•Cambridge, MA

9d•$360,000 - $408,000•Hybrid

About The Position

Prime Medicine is seeking an experienced, strategic, and operationally rigorous Development Asset Leader to lead its in vivo LNP-delivered liver programs as they progress from early clinical development through licensure, beginning with the Wilson’s Disease and Alpha-1 Antitrypsin Deficiency programs. The leader assumes ownership once a liver program has cleared IND and is accountable for the asset through clinical proof of concept and regulatory approval or licensure. As the liver portfolio grows, the role is expected to expand from ownership of a single asset to franchise-level leadership, developing processes, governance, and team structures to support multiple concurrent clinical assets. The role combines cross-functional team leadership with accountability for timelines, budgets, and scientific rigor, as well as engagement with executive management, the Board, regulatory authorities, key opinion leaders, and CRO/CDMO leadership. The position is based in Cambridge, Massachusetts, with a minimum of three days per week onsite. It reports to the VP, Programs and Strategy and is designated at the VP level. The role is eligible for annual short-term incentive and long-term incentive awards. The stated U.S. base salary range is $360,000–$408,000.

Requirements

12+ years of drug development experience in biotech or pharma, with demonstrated leadership of a clinical-stage asset from IND through late-stage development.
Track record of cross-functional program leadership and accountability spanning Clinical, Regulatory, CMC, and Nonclinical.
Demonstrated ability to influence without formal authority, build team culture, and manage external partners such as consultants, CROs, and KOLs as an extension of the internal team.
Comfort operating in a lean, resource-constrained organization where the Asset Leader is expected to build capability.

Nice To Haves

Advanced degree in life sciences, medicine, or a related field (PhD, MD, or PharmD); equivalent industry experience is considered.
Direct experience in genetic medicines, including gene or gene-editing therapies or RNA-based therapeutics, or in rare disease.
Liver-directed or LNP delivery experience.
Experience or genuine interest in applying AI tools to project or portfolio management.

Responsibilities

Own the Integrated Development Plan for liver assets from IND acceptance through regulatory approval or licensure, including trial design input, data package strategy, and key go/no-go decision points.
Anticipate, frame, and escalate critical considerations that materially affect an asset’s risk/value profile to executive management.
Lead a matrixed team spanning Clinical, Regulatory, CMC/Manufacturing, Biostatistics, Pharmacovigilance, Medical Affairs/Patient Advocacy, and Commercial.
Deploy AI-enabled project-management tools where appropriate, including timelines, risk registers, and cross-functional dashboards.
Help design team structure, governance cadence, and knowledge-transfer processes as the liver franchise expands.
Serve as a key point of contact with CROs/CDMOs, KOLs, and patient advocacy groups for the asset.
Represent the asset in regulatory interactions alongside Regulatory Affairs.